Literature DB >> 19165866

Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.

Michael Keese1, Lala Gasimova, Kay Schwenke, Vugar Yagublu, Edward Shang, Ralf Faissner, Andrew Lewis, Stefan Samel, Matthias Löhr.   

Abstract

We investigated the therapeutic efficiency of sulfonate-modified polyvinyl alcohol beads loaded with doxorubicin, irinotecan or mitoxantrone in vitro and in vivo in a model of experimental peritoneal carcinomatosis (PC). In vitro, cell proliferation was efficiently impaired by doxorubicin drug eluting bead (DEB) treatment while mitoxantrone DEBs were less effective than. Irinotecan showed little effect for both DEBs and free drug. Apoptosis was not different between free mitoxantrone and the DEB form while more apoptosis induction was observed in cells incubated with free doxorubicin and irinotecan. Experimental PC was produced in mice. The therapeutic efficiency of either mitoxantrone and doxorubicin DEB or free drugs were compared. Mice were treated either once on day 12 or by 3 repetitive applications on days 7, 10 and 12. Mice treated by DEBs showed less weight loss and mortality. Therapeutic effect was determined by measuring tumor volume and tumor load on the day 15 after tumor inoculation. For the single application on the day 12, an advantage could be observed for the free drugs. After 3 repeated injections of both free and mitoxantrone DEB no difference in tumor load or tumor volume could be observed. Least tumor load and tumor volume was observed in mice that received 3 repeated injections of doxorubicin DEB. No animal survived 3 injections of free doxorubicin. We conclude that bead encapsulation of chemotherapeutic drugs may show the advantage of less toxicity in peritoneal spread of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165866     DOI: 10.1002/ijc.24211

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy.

Authors:  Andrew L Lewis; Matthew R Dreher
Journal:  J Control Release       Date:  2012-01-21       Impact factor: 9.776

Review 2.  Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.

Authors:  Simon Binder; Andrew L Lewis; J-Matthias Löhr; Michael Keese
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

3.  Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.

Authors:  Richard E J Forster; Sharon A Small; Yiqing Tang; Clare L Heaysman; Andrew W Lloyd; Wendy Macfarlane; Gary J Phillips; Milan D Antonijevic; Andrew L Lewis
Journal:  J Mater Sci Mater Med       Date:  2010-06-19       Impact factor: 3.896

4.  SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation.

Authors:  Johannes M Ludwig; Yongkang Gai; Lingyi Sun; Guangya Xiang; Dexing Zeng; Hyun S Kim
Journal:  Mol Oncol       Date:  2016-05-21       Impact factor: 6.603

5.  Vandetanib-eluting Radiopaque Beads: In vivo Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization.

Authors:  Alban Denys; Peter Czuczman; David Grey; Zainab Bascal; Rhys Whomsley; Hugh Kilpatrick; Andrew L Lewis
Journal:  Theranostics       Date:  2017-06-01       Impact factor: 11.556

Review 6.  Colorectal Peritoneal Metastases: A Systematic Review of Current and Emerging Trends in Clinical and Translational Research.

Authors:  Foteini Stefania Koumpa; Diamantis Xylas; Maciej Konopka; Dieter Galea; Kirill Veselkov; Anthony Antoniou; Akash Mehta; Reza Mirnezami
Journal:  Gastroenterol Res Pract       Date:  2019-04-01       Impact factor: 2.260

Review 7.  Intraperitoneal drug delivery systems releasing cytostatic agents to target gastro-intestinal peritoneal metastases in laboratory animals: a systematic review.

Authors:  Anne G W E Wintjens; Geert A Simkens; Peter-Paul K H Fransen; Narcis Serafras; Kaatje Lenaerts; Gregor H L M Franssen; Ignace H J T de Hingh; Patricia Y W Dankers; Nicole D Bouvy; Andrea Peeters
Journal:  Clin Exp Metastasis       Date:  2022-06-23       Impact factor: 4.510

8.  "A novel highly stable and injectable hydrogel based on a conformationally restricted ultrashort peptide".

Authors:  Chaitanya Kumar Thota; Nitin Yadav; Virander Singh Chauhan
Journal:  Sci Rep       Date:  2016-08-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.